Orchard sets out to sell world’s priciest gene therapy

Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market. 

By Kristin Jensen • March 20, 2024

With historic MASH approval, Madrigal preps for launch and a public offering

After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.

By Amy Baxter • March 20, 2024

Ex-Novartis exec sets out to create ‘Apple of AI’

Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.

By Kelly Bilodeau • March 18, 2024

Amylyx ALS drug fails crucial study, putting company’s future in doubt

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

By Jacob Bell • Updated March 8, 2024

Ozempic for liver disease? Weight loss drugs could have even more to offer

GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

By Kelly Bilodeau • Feb. 26, 2024

How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

By Alexandra Pecci • Feb. 26, 2024

BioMarin preaches patience amid slow sales for hemophilia gene therapy

The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

By Ben Fidler • Feb. 23, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

3 questions hanging over the Novo-Catalent deal

As backlash builds for the recently announced matchup, critical questions remain over its impact.

By Kelly Bilodeau • Feb. 13, 2024

These 4 drugs had tons of promise — and they flopped. What happened?

No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

By Alexandra Pecci • Feb. 13, 2024

Could Novo, Lilly become first trillion-dollar healthcare companies?

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

By Meagan Parrish • Feb. 2, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

What are pharma’s next blockbusters?

In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

By Kelly Bilodeau • Dec. 20, 2023

Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

By Michael Gibney • Dec. 12, 2023

Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

By Alexandra Pecci • Dec. 11, 2023

What if a CRISPR cure isn’t such an easy choice?

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023

What’s next for COVID dark horse Novavax?

Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

By Kelly Bilodeau • Oct. 30, 2023

Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

3 marketing tips for biotechs emerging from stealth

In a crowded biotech market, here’s how your company can stand out to investors.

By Karissa Waddick • Oct. 6, 2023

PharmaVoice 100s: Brand and commercialization pros

Leaders decoding the complex language of drug development to push treatments past the finish line and into patients’ hands.

By Karissa Waddick • Oct. 4, 2023

How pharma marketers can reclaim the drug pricing narrative

As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

By Karissa Waddick • Sept. 28, 2023

Optimizing your hub services program with a gross-to-net lens

In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.

Sept. 25, 2023

As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

By Michael Gibney • Sept. 14, 2023